 Whales Enter Biopharma: Who Bought $100M+ in Stocks Analysis of recent insider purchases as of May 11, 2026. Most notable deals: 1. **Genedx Holdings (WGS)** — $46.8 million Kate Meister (well-known activist investor) bought 1.2 million shares at $38.84. Stake increased by 34%. This is the largest insider purchase of the day and a strong signal: Meister doesn't enter without a strategy. 2. **Odyssey Therapeutics (ODTX)** — $20 million + $10 million Two insiders simultaneously: Director Nan Li bought $20 million (+50% to stake) and fund Sr One Capital Management added another $10 million. Total $30 million — a level of confidence. 3. **Pulse Biosciences (PLSE)** — $13 million Robert Duggan, director and 10% shareholder, bought 660,000 shares. His stake was already huge — 49 million shares — but he continues to increase. 4. **Mobia Medical (MOBI)** — $8 million + $1.9 million William Harrington increased his stake by 61%, Cynthia Lucchese opened a new position. **Trend:** Biopharma = main magnet for insiders 6 out of 10 largest purchases are in biotech and pharma. Analysts confirm: the sector combines the AI revolution with fundamental undervaluation. Companies like Recursion Pharma, Genmab, BioCryst attract attention from large funds. **What this means:** When directors and 10% shareholders invest their own money — it's an above-average signal. Especially when purchases are in the tens of millions of dollars. Source: OpenInsider, NewsAPI